PDGFRB and neoplasm: Anlotinib is an orally administered multi-targeted TKI that exerts antitumor effects through the simultaneous inhibition of tumor angiogenesis and tumor cell proliferation by selectively targeting FGFR, VEGFR, PDGFR, RET, and c-Kit (40).